Stereotaxis will participate in the Piper Sandler Healthcare Conference, discussing regulatory milestones and growth opportunities.
Quiver AI Summary
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular procedures, announced its participation in the Piper Sandler 37th Annual Healthcare Conference, where Chairman and CEO David Fischel will engage in a fireside chat on December 3rd, 2025, and will be available for one-on-one meetings. Fischel stated that the company is experiencing significant growth and key regulatory milestones, expressing eagerness to connect with investors at the event. Stereotaxis provides advanced robotic systems and solutions that enhance patient care and operational efficiency in interventional laboratories, having treated over 150,000 patients globally. The press release also contains forward-looking statements regarding the company’s future prospects, emphasizing inherent risks and uncertainties.
Potential Positives
- Participation in the Piper Sandler 37th Annual Healthcare Conference, which provides visibility and engagement opportunities with investors.
- CEO David Fischel's involvement in a fireside discussion indicates the company's commitment to transparency and investor relations.
- Management highlights achieving key regulatory milestones and early commercial growth, suggesting positive momentum for the company's operations.
- Stereotaxis has a proven track record, having treated over 150,000 patients globally, underscoring the effectiveness and acceptance of its technology.
Potential Negatives
- The press release includes a prominent disclaimer regarding forward-looking statements, highlighting significant risks and uncertainties that could materially affect the company's future results.
- There is no assurance provided that the company will recognize revenue from customer purchase orders, indicating potential financial instability.
- The mention of the need to manage expenses at sustainable levels suggests concerns about the company's cost structure and financial health.
FAQ
When is Stereotaxis participating in the Piper Sandler Healthcare Conference?
Stereotaxis will participate on December 3rd, 2025, at 9:00 am Eastern Standard Time.
Who is speaking at the conference for Stereotaxis?
David Fischel, Chairman and CEO of Stereotaxis, will speak at the conference.
What topics will Stereotaxis discuss at the conference?
They will discuss key regulatory milestones and early commercial growth during the conference.
How can investors get in touch with Stereotaxis?
Investors can arrange one-on-one meetings with Stereotaxis representatives on the same day of the conference.
What is the mission of Stereotaxis?
Stereotaxis aims to advance surgical robotics for minimally invasive endovascular interventions and improve patient care.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$STXS Insider Trading Activity
$STXS insiders have traded $STXS stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $STXS stock by insiders over the last 6 months:
- PAUL J ISAAC has made 2 purchases buying 30,000 shares for an estimated $66,600 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$STXS Hedge Fund Activity
We have seen 51 institutional investors add shares of $STXS stock to their portfolio, and 34 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STATE OF WYOMING removed 392,567 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,220,883
- TWO SIGMA INVESTMENTS, LP added 361,888 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,125,471
- RENAISSANCE TECHNOLOGIES LLC added 336,600 shares (+768.5%) to their portfolio in Q3 2025, for an estimated $1,046,826
- PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. removed 238,000 shares (-20.9%) from their portfolio in Q3 2025, for an estimated $740,180
- TWO SIGMA ADVISERS, LP added 171,600 shares (+inf%) to their portfolio in Q3 2025, for an estimated $533,676
- WARBERG ASSET MANAGEMENT LLC removed 151,633 shares (-12.6%) from their portfolio in Q3 2025, for an estimated $471,578
- JANE STREET GROUP, LLC added 140,766 shares (+382.6%) to their portfolio in Q3 2025, for an estimated $437,782
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
ST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the company will participate in the Piper Sandler 37th Annual Healthcare Conference .
David Fischel, Stereotaxis Chairman and CEO, is scheduled to participate in a fireside discussion on Wednesday, December 3 rd , 2025, at 9:00 am Eastern Standard Time and will be available that same day for one-on-one meetings.
“This is an exciting period for Stereotaxis as we achieve key regulatory milestones and demonstrate early commercial growth," said Mr. Fischel. "We look forward to engaging with investors at the Piper Sandler conference."
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit
www.stereotaxis.com
.
This press release includes statements that may constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934, including statements regarding the completion of the Company’s offering and the anticipated use of proceeds therefrom, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the SEC. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this press release. There can be no assurance that the Company will recognize revenue related to customer purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
[email protected]
